Safinamide for the treatment of Parkinson's disease, epilepsy and restless legs syndrome.
Merck Serono SA (formerly Serono), under license from Newron Pharmaceuticals SpA (following its acquisition of the rights from Pharmacia and Upjohn AB [now Pfizer Inc]), is developing the oral alpha-aminoamide derivative of milacemide, safinamide, a monoamine oxidase-B and glutamate release inhibitor, for the potential treatment of Parkinson's disease, epilepsy and restless legs syndrome. In March 2007, plans to develop the agent for the potential treatment of other cognitive disorders, such as Alzheimer's disease, were being finalized and testing was expected to begin before the end of that year.
Durham University, Centre for Integrative Neuroscience (CINS), School of Biological and Biomedical Sciences, South Road, Durham DH1 3LE, UK. paul.chazot@durham.ac.uk
Paul L
PL
Chazot
D000409:Alanine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D000818:Animals; D001596:Benzylamines / Q000737:chemistry / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D015394:Molecular Structure; D008995:Monoamine Oxidase / Q000378:metabolism; D008996:Monoamine Oxidase Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D010300:Parkinson Disease / Q000188:drug therapy* / Q000503:physiopathology; D012148:Restless Legs Syndrome / Q000188:drug therapy*
D001596:Benzylamines; D008996:Monoamine Oxidase Inhibitors; C092797:safinamide; D008995:Monoamine Oxidase; D000409:Alanine